111 related articles for article (PubMed ID: 9827821)
1. Liposomal busulphan: bioavailability and effect on bone marrow in mice.
Hassan Z; Nilsson C; Hassan M
Bone Marrow Transplant; 1998 Nov; 22(9):913-8. PubMed ID: 9827821
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of liposomal busulphan as an intravenous myeloablative agent prior to stem cell transplantation: 500 mg/m(2) as a optimal total dose for conditioning.
Hassan M; Nilsson C; Hassan Z; Gungor T; Aschan J; Winiarski J; Hentschke P; Ringdén O; Eber S; Seger R; Ljungman P
Bone Marrow Transplant; 2002 Dec; 30(12):833-41. PubMed ID: 12476274
[TBL] [Abstract][Full Text] [Related]
3. Effect of altering administration order of busulphan and cyclophosphamide on the myeloablative and immunosuppressive properties of the conditioning regimen in mice.
Nilsson C; Forsman J; Hassan Z; Abedi-Valugerdi M; O'Connor C; Concha H; Jansson M; Hassan M
Exp Hematol; 2005 Mar; 33(3):380-7. PubMed ID: 15730862
[TBL] [Abstract][Full Text] [Related]
4. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of liposomal busulphan in man.
Hassan Z; Ljungman P; Ringdén O; Winiarski J; Nilsson C; Aschan J; Whitley HR; Hassan M
Bone Marrow Transplant; 2001 Mar; 27(5):479-85. PubMed ID: 11313681
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation.
Schuler US; Ehrsam M; Schneider A; Schmidt H; Deeg J; Ehninger G
Bone Marrow Transplant; 1998 Aug; 22(3):241-4. PubMed ID: 9720736
[TBL] [Abstract][Full Text] [Related]
7. The effect of modulation of glutathione cellular content on busulphan-induced cytotoxicity on hematopoietic cells in vitro and in vivo.
Hassan Z; Hellström-Lindberg E; Alsadi S; Edgren M; Hägglund H; Hassan M
Bone Marrow Transplant; 2002 Aug; 30(3):141-7. PubMed ID: 12189531
[TBL] [Abstract][Full Text] [Related]
8. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders.
Hassan M; Fasth A; Gerritsen B; Haraldsson A; Syrůcková Z; van den Berg H; Sandström M; Karlsson M; Kumlien S; Vossen J
Bone Marrow Transplant; 1996 Nov; 18(5):843-50. PubMed ID: 8932835
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oral busulphan in children with beta thalassaemia major undergoing allogeneic bone marrow transplantation.
Poonkuzhali B; Srivastava A; Quernin MH; Dennison D; Aigrain EJ; Kanagasabapathy AS; Krishnamoorthy R; Chandy M
Bone Marrow Transplant; 1999 Jul; 24(1):5-11. PubMed ID: 10435727
[TBL] [Abstract][Full Text] [Related]
10. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Schuler US; Renner UD; Kroschinsky F; Johne C; Jenke A; Naumann R; Bornhäuser M; Deeg HJ; Ehninger G
Br J Haematol; 2001 Sep; 114(4):944-50. PubMed ID: 11564090
[TBL] [Abstract][Full Text] [Related]
11. Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.
Brice K; Valerie B; Claire G; Valerie M; Yves B; Gilles A; Nathalie B
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):135-43. PubMed ID: 17952879
[TBL] [Abstract][Full Text] [Related]
12. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.
Grochow LB
Semin Oncol; 1993 Aug; 20(4 Suppl 4):18-25; quiz 26. PubMed ID: 8342071
[TBL] [Abstract][Full Text] [Related]
13. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
14. An analysis of haemopoietic and microenvironmental populations of mouse bone marrow after treatment with busulphan.
Molineux G; Testa NG; Massa G; Schofield R
Biomed Pharmacother; 1986; 40(6):215-20. PubMed ID: 3539222
[TBL] [Abstract][Full Text] [Related]
15. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
Tran HT; Madden T; Petropoulos D; Worth LL; Felix EA; Sprigg-Saenz HA; Choroszy M; Danielson M; Przepiorka D; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(5):463-70. PubMed ID: 11019834
[TBL] [Abstract][Full Text] [Related]
16. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.
Bleyzac N; Souillet G; Magron P; Janoly A; Martin P; Bertrand Y; Galambrun C; Dai Q; Maire P; Jelliffe RW; Aulagner G
Bone Marrow Transplant; 2001 Oct; 28(8):743-51. PubMed ID: 11781625
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologically-guided dose adjustment of busulfan in high-dose chemotherapy regimens: rationale and pitfalls (review).
Vassal G
Anticancer Res; 1994; 14(6A):2363-70. PubMed ID: 7825973
[TBL] [Abstract][Full Text] [Related]
18. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
19. Busulphan given as four single daily doses of 150 mg/m2 is safe and effective in children of all ages.
Shaw PJ; Nath C; Berry A; Earl JW
Bone Marrow Transplant; 2004 Aug; 34(3):197-205. PubMed ID: 15195074
[TBL] [Abstract][Full Text] [Related]
20. The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model.
Sadeghi B; Jansson M; Hassan Z; Mints M; Hägglund H; Abedi-Valugerdi M; Hassan M
Bone Marrow Transplant; 2008 May; 41(10):895-904. PubMed ID: 18223695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
